Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study
Pediatrics International · 2026
DOI: 10.1111/ped.70301 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Pediatrics International, 2026. Verfasst von Kouji Masumoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Parenteral Nutrition, Peptides, Short Bowel Syndrome. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Background
Patients with short bowel syndrome (SBS)‐associated intestinal failure (SBS‐IF) are dependent on parenteral support (PS). In Japan, teduglutide is the only GLP‐2 analog medicine indicated for these patients. There are limited data for pediatric patients, especially those with a low body weight. This study evaluated the safety and efficacy of teduglutide in Japanese pediatric patients with SBS‐IF (dependence on PS to provide ≥30% of fluid or caloric intake needs) who weighed less than 10 kg.
Methods
This phase 3, open‐label study enrolled Japanese pediatric patients with SBS‐IF. Patients weighing less than 10 kg received teduglutide 0.05 mg/kg/day subcutaneously in 28‐week treatment cycles (24 weeks of teduglutide treatment and 4 weeks of follow‐up). Adverse events, changes in PS requirements, and growth parameters were assessed.
Results
Three patients completed the study, with a mean teduglutide exposure duration of 48.9 weeks. All patients experienced treatment‐emergent adverse events (TEAEs), but none were related to the study drug or led to death or treatment discontinuation. Clinically meaningful reductions in mean PS volume (13.1%) and mean PS caloric intake (46.6%) were observed at the end of treatment from baseline. One patient achieved a reduction in PS volume of ≥20% at the end of treatment from baseline. Growth parameters showed increases in weight and height/length‐for‐age z ‐scores at the end of treatment from baseline.
Conclusion
In the three patients with SBS‐IF who weighed less than 10 kg, no new safety signals were observed following teduglutide treatment. Clinically meaningful reductions in PS were noted and there was no adverse impact on growth parameters. Trial Registration ClinicalTrials.gov registration number: NCT05027308
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
- Department of Pediatric Surgery, Research Field in Medical and Health Sciences, Medical and Dental Area, Research and Education Assembly, Kagoshima University, Kagoshima, Japan.
- Takeda Pharmaceutical Company Limited, Osaka, Japan.
- Takeda Pharmaceutical Company Limited, Tokyo, Japan.
ORCID-Profile: Kouji Masumoto, Mitsuru Muto, Takato Sasaki, Mitsuhiro Shikamura, Hiroya Nakano, Taisuke Kondo, Satoshi Ieiri
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Masumoto, K., Muto, M., Sasaki, T., Shikamura, M., Tanaka, T., Sakui, S., Miyamoto, M., Nakano, H., Kondo, T., & Ieiri, S. (2026). Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study. Pediatrics International. https://doi.org/10.1111/ped.70301
Vancouver
Masumoto K, Muto M, Sasaki T, Shikamura M, Tanaka T, Sakui S, et al. Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study. Pediatrics International. 2026. doi:10.1111/ped.70301
BibTeX
@article{Masumoto2026,
author = {Masumoto, Kouji and Muto, Mitsuru and Sasaki, Takato and Shikamura, Mitsuhiro and Tanaka, Tomoko and Sakui, Sho and Miyamoto, Masakazu and Nakano, Hiroya and Kondo, Taisuke and Ieiri, Satoshi},
title = {Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study},
journal = {Pediatrics International},
year = {2026},
doi = {10.1111/ped.70301}
}
EUVIMED